Innoviva Specialty Therapeutics (INVA) Partners With Dr. Reddy’s to Expand XACDURO Access Internationally

Innoviva Inc. (NASDAQ:INVA) is one of the most profitable undervalued stocks to invest in. On June 16, Innoviva Specialty Therapeutics entered an exclusive licensing and distribution agreement with Dr. Reddy’s Laboratories to bring XACDURO to South and Central America, the Caribbean, Russia, and the CIS region. The partnership aims to address a critical health challenge, as carbapenem-resistant Acinetobacter infection rates in these areas exceed 70%.

Under the deal, Dr. Reddy’s will manage the development, regulatory approval, and commercialization of the antibiotic within these territories. Innoviva retains rights in all other regions and is set to receive an upfront payment, along with milestone payments and tiered royalties based on future net sales.

XACDURO, which is FDA-approved for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter, is considered a vital tool against this “critical threat” pathogen. By using Dr. Reddy’s regional expertise, Innoviva Inc. (NASDAQ:INVA) intends to broaden global access to this specialized treatment while maintaining its strategic focus.

Innoviva Specialty Therapeutics (INVA) Partners With Dr. Reddy’s to Expand XACDURO Access Internationally

15 States with the Best Healthcare in the US

Innoviva Inc. (NASDAQ:INVA) is a diversified holding company that manages a portfolio of biopharmaceutical royalties and invests in, develops, and commercializes healthcare assets. Its core business focuses on royalties from respiratory products (RELVAR/BREO and ANORO ELLIPTA) partnered with GSK, alongside a specialized therapeutic platform, Innoviva Specialty Therapeutics, focused on critical care and infectious diseases.

While we acknowledge the risk and potential of INVA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than INVA and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1